Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study (Q38471162)

3 September 2017

title

Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study (English)

1 reference

3 September 2017

author name string

Francisco A H Fonseca

series ordinal

1

1 reference

3 September 2017

Maria Cristina O Izar

series ordinal

2

1 reference

3 September 2017

publication date

1 September 2009

1 reference

Expert Review of Cardiovascular Therapy

3 September 2017

published in

1 reference

3 September 2017

volume

7

1 reference

3 September 2017

issue

9

1 reference

3 September 2017

page(s)

1041-1056

1 reference

Commentary: C-reactive protein and risk prediction--moving beyond associations to assessing predictive utility and clinical usefulness

3 September 2017

cites work

1 reference

Major risk factors as antecedents of fatal and nonfatal coronary heart disease events

21 January 2018

1 reference

The molecular mechanisms of the thrombotic complications of atherosclerosis

21 January 2018

1 reference

From vulnerable plaque to atherothrombosis.

21 January 2018

1 reference

Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts

21 January 2018

1 reference

Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group

21 January 2018

1 reference

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men

21 January 2018

1 reference

Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events

21 January 2018

1 reference

Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women

21 January 2018

1 reference

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

21 January 2018

1 reference

Inflammatory markers and the risk of coronary heart disease in men and women

21 January 2018

1 reference

C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany

21 January 2018

1 reference

Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study

21 January 2018

1 reference

C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease

21 January 2018

1 reference

Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events

21 January 2018

1 reference

Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial

21 January 2018

1 reference

Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease

21 January 2018

1 reference

C-reactive protein levels and outcomes after statin therapy

21 January 2018

1 reference

Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22.

21 January 2018

1 reference

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial

21 January 2018

1 reference

Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial

21 January 2018

1 reference

Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein

21 January 2018

1 reference

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial

21 January 2018

1 reference

Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis

21 January 2018

1 reference

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

21 January 2018

1 reference

A randomized trial of rosuvastatin in the prevention of venous thromboembolism

21 January 2018

1 reference

Statins and blood coagulation

21 January 2018

1 reference

Effects of lipids and lipid-lowering therapy on hemostatic factors in patients with myocardial infarction

21 January 2018

1 reference

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study

21 January 2018

1 reference

Modulation of Coagulation and Fibrinolytic Pathways by Statins

21 January 2018

1 reference

Use of statins and the subsequent development of deep vein thrombosis

21 January 2018

1 reference

HMG CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women

21 January 2018

1 reference

Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital-based case-control study

21 January 2018

1 reference

The JUPITER trial: results, controversies, and implications for prevention

21 January 2018

1 reference

The editor's roundtable: the JUPITER trial--initial results and clinical implications

21 January 2018

1 reference

CRP is a novel ligand for the oxidized LDL receptor LOX-1.

21 January 2018

1 reference

C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice.

21 January 2018

1 reference

The inextricable link between atherosclerosis and prototypical inflammatory diseases rheumatoid arthritis and systemic lupus erythematosus

21 January 2018

1 reference

Atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus

21 January 2018

1 reference

Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy

21 January 2018

1 reference

Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event

21 January 2018

1 reference

Pleiotropic effects of statin therapy: molecular mechanisms and clinical results.

21 January 2018

1 reference

Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation

21 January 2018

1 reference

The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.

21 January 2018

1 reference

Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial

21 January 2018

1 reference

Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials

21 January 2018

1 reference

Statins and C-reactive protein levels

21 January 2018

1 reference

Tracking of high-sensitivity C-reactive protein after an initially elevated concentration: the JUPITER Study

21 January 2018

1 reference

Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk

21 January 2018

1 reference

Genetically elevated C-reactive protein and ischemic vascular disease

21 January 2018

1 reference

Influence of short-term rosuvastatin therapy on endothelial progenitor cells and endothelial function

21 January 2018

1 reference

Effect of intensive vs standard statin therapy on endothelial progenitor cells and left ventricular function in patients with acute myocardial infarction: Statins for regeneration after acute myocardial infarction and PCI (STRAP) trial

21 January 2018

1 reference

Role of inflammation and oxidative stress in endothelial progenitor cell function and mobilization: therapeutic implications for cardiovascular diseases

21 January 2018

1 reference

Rho/Rho-kinase pathway contributes to C-reactive protein-induced plasminogen activator inhibitor-1 expression in endothelial cells

21 January 2018

1 reference

Impact of statins on modulation by insulin of expression of plasminogen activator inhibitor type-1.

21 January 2018

1 reference

Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastat

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERC.09.93

1 reference

3 September 2017

1 reference